瑞替普酶溶栓治疗急性心肌梗死25例临床分 析简

目的：观察瑞替普酶治疗急性ST段抬高型心肌梗死的疗效及安全性.方法：选取符合溶栓条件的急性心肌梗死患者25 例,采用瑞替普酶18 mg 缓慢推注2 min 以上,半小时后重复给予-次的方法.观察冠脉血管再通率、不良反应及病死率.结果：溶栓总再通率92%,其中发病2 h内溶栓再通率100%,2 ～ 6 h内再通率88.9%.结论：瑞替普酶是治疗急性心肌梗死安全可靠、方便快捷的溶栓药物,在不具备介入治疗条件的基层医院值得临床推广.

The clinical analysis of reteplase thrombolytic therapy in 25 cases with acute myocardial infarction

Objective： To observe the efficacy and safety of reteplase on the treatment of acute ST elevation myocardialinfarction. Methods： A total of 25 cases of patients with acute myocardial infarction who were eligible for thrombolysis were treatedwith reteplase 18 mg by slow intravenous injection （about 2 minutes or more）, and reteplase was given again after half an hour. Thecoronary recanalization rate, adverse reactions and mortality were observed. Results： The total thrombolytic recanalization rate was92%, it was 100% in the patients used reteplase within 2 h, and 88.9% within 2 – 6 h. Conclusion： Reteplase is a safe, reliable,convenient and efficient drug on the treatment of acute myocardial infarction, which can be used widely in the primary hospital withno condition for interventional therapy.